Esophageal Cancer Treatment Landscape Evolves with Novel Therapies and Approvals
• The esophageal cancer market is expected to grow significantly, driven by increasing prevalence and the introduction of novel therapies.
• In 2023, approximately 77,000 new cases of esophageal cancer were reported across seven major markets, with Japan having the highest number.
• Recent FDA approval of TEVIMBRA (tislelizumab) as a monotherapy marks a significant advancement in treating unresectable or metastatic ESCC.
• Emerging therapies like zanidatamab and bemarituzumab are expected to revolutionize the esophageal cancer market dynamics during the forecast period.
© Copyright 2025. All Rights Reserved by MedPath